Hims & Hers Health (NYSE:HIMS) PT Lowered to $6.00

Hims & Hers Health (NYSE:HIMSGet Rating) had its target price dropped by equities research analysts at Piper Sandler from $8.00 to $6.00 in a research note issued on Thursday, The Fly reports. Piper Sandler’s target price would suggest a potential upside of 67.13% from the stock’s previous close.

HIMS has been the subject of a number of other research reports. Zacks Investment Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 11th. Citigroup decreased their price target on Hims & Hers Health from $9.00 to $6.00 in a research report on Tuesday, May 10th. Guggenheim assumed coverage on Hims & Hers Health in a research report on Wednesday, April 13th. They issued a “buy” rating and a $10.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Hims & Hers Health in a research report on Thursday, March 10th. They issued a “hold” rating and a $7.00 price target for the company. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Buy” and an average target price of $8.14.

NYSE HIMS opened at $3.59 on Thursday. The stock has a market cap of $736.21 million, a PE ratio of -9.97 and a beta of 0.38. Hims & Hers Health has a fifty-two week low of $2.72 and a fifty-two week high of $15.55. The business has a 50 day moving average price of $4.55 and a two-hundred day moving average price of $5.30.

Hims & Hers Health (NYSE:HIMSGet Rating) last announced its earnings results on Monday, May 9th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. Hims & Hers Health had a negative return on equity of 22.41% and a negative net margin of 22.60%. The business had revenue of $101.30 million during the quarter, compared to analysts’ expectations of $90.99 million. During the same quarter last year, the business posted ($0.14) earnings per share. The company’s quarterly revenue was up 93.7% on a year-over-year basis. Equities analysts anticipate that Hims & Hers Health will post -0.37 EPS for the current fiscal year.

In other news, Director Lynne Chou O’keefe sold 10,044 shares of the business’s stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $4.50, for a total transaction of $45,198.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patrick Harrison Carroll sold 86,820 shares of the business’s stock in a transaction on Monday, February 28th. The stock was sold at an average price of $5.17, for a total value of $448,859.40. The disclosure for this sale can be found here. 43.70% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new position in Hims & Hers Health in the third quarter valued at about $1,524,000. PEAK6 Investments LLC acquired a new position in shares of Hims & Hers Health during the third quarter worth about $885,000. Renaissance Technologies LLC boosted its position in shares of Hims & Hers Health by 8,925.1% during the third quarter. Renaissance Technologies LLC now owns 1,579,400 shares of the company’s stock worth $11,909,000 after buying an additional 1,561,900 shares during the period. Chiron Capital Management LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth about $90,000. Finally, Capstone Investment Advisors LLC acquired a new position in shares of Hims & Hers Health during the third quarter worth about $132,000. 57.22% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health (Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Featured Stories

The Fly logo

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.